SG10202105964RA - Hpk1 inhibitors and methods of using same - Google Patents

Hpk1 inhibitors and methods of using same

Info

Publication number
SG10202105964RA
SG10202105964RA SG10202105964RA SG10202105964RA SG10202105964RA SG 10202105964R A SG10202105964R A SG 10202105964RA SG 10202105964R A SG10202105964R A SG 10202105964RA SG 10202105964R A SG10202105964R A SG 10202105964RA SG 10202105964R A SG10202105964R A SG 10202105964RA
Authority
SG
Singapore
Prior art keywords
methods
same
hpk1 inhibitors
hpk1
inhibitors
Prior art date
Application number
SG10202105964RA
Other languages
English (en)
Inventor
Peter Brent Sampson
Narendra Kumar B Patel
Heinz W Pauls
Sze-Wan Li
Grace Ng
Radoslaw Laufer
Yong Liu
Yunhui Lang
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of SG10202105964RA publication Critical patent/SG10202105964RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
SG10202105964RA 2015-06-25 2016-06-23 Hpk1 inhibitors and methods of using same SG10202105964RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562184348P 2015-06-25 2015-06-25

Publications (1)

Publication Number Publication Date
SG10202105964RA true SG10202105964RA (en) 2021-07-29

Family

ID=57584335

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202105964RA SG10202105964RA (en) 2015-06-25 2016-06-23 Hpk1 inhibitors and methods of using same

Country Status (27)

Country Link
US (3) US10501474B2 (fr)
EP (1) EP3322711B1 (fr)
JP (3) JP6898868B2 (fr)
KR (2) KR102614872B1 (fr)
CN (2) CN107922431B (fr)
AU (1) AU2016282289B2 (fr)
BR (2) BR112017027241B1 (fr)
CA (1) CA2989684A1 (fr)
CY (1) CY1124489T1 (fr)
DK (1) DK3322711T3 (fr)
EA (1) EA035421B1 (fr)
ES (1) ES2872555T3 (fr)
HK (1) HK1255833A1 (fr)
HR (1) HRP20210895T1 (fr)
HU (1) HUE054159T2 (fr)
IL (2) IL283353B (fr)
LT (1) LT3322711T (fr)
MA (1) MA42456B1 (fr)
MD (1) MD3322711T2 (fr)
MX (2) MX2018000048A (fr)
PL (1) PL3322711T3 (fr)
PT (1) PT3322711T (fr)
RS (1) RS61919B1 (fr)
SG (1) SG10202105964RA (fr)
SI (1) SI3322711T1 (fr)
TW (1) TWI733679B (fr)
WO (1) WO2016205942A1 (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3322711T (lt) * 2015-06-25 2021-05-10 University Health Network Hpk1 inhibitoriai ir jų panaudojimo būdai
AU2017322427B2 (en) 2016-09-09 2021-12-23 Incyte Corporation Pyrazolopyridine derivatives as HPK1 modulators and uses thereof for the treatment of cancer
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
US20180228786A1 (en) * 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2018167147A1 (fr) * 2017-03-15 2018-09-20 F. Hoffmann-La Roche Ag Azaindoles utilisés en tant qu'inhibiteurs de hpk1
WO2018183964A1 (fr) * 2017-03-30 2018-10-04 Genentech, Inc. Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
BR112019018093A2 (pt) 2017-03-30 2020-06-16 F. Hoffmann-La Roche Ag Compostos, composição, método de inibição de hpk1, métodos para melhorar uma resposta imune e para tratar um distúrbio e usos do composto
WO2018228923A1 (fr) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Dérivés de pyrrolopyridine substitués utilisés en tant que modulateurs de map4k1 pour le traitement de maladies cancéreuses
WO2018228925A1 (fr) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Dérivés de pyrrolopyridine substitués
CA3066859A1 (fr) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Derives de pyrrolopyridine substitues
EP3655406A1 (fr) 2017-07-18 2020-05-27 Bayer Pharma Aktiengesellschaft Dérivés de pyrrolopyridine substitués
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
CN109721620B (zh) * 2017-10-27 2022-05-13 药捷安康(南京)科技股份有限公司 Hpk1抑制剂及其用途
EP3707138B1 (fr) * 2017-11-06 2022-07-13 Bristol-Myers Squibb Company Composés d'isofuranone utiles en tant qu'inhibiteurs de hpk1
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
PL3755703T3 (pl) * 2018-02-20 2022-11-07 Incyte Corporation Pochodne n-(fenylo)-2-(fenylo)pirymidyno-4-karboksyamidu i związki pokrewne jako inhibitory hpk1 do leczenia nowotworu
WO2019164847A1 (fr) 2018-02-20 2019-08-29 Incyte Corporation Composés d'indazole et leurs utilisations
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
TW202019905A (zh) * 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
CN112533677A (zh) 2018-07-24 2021-03-19 豪夫迈·罗氏有限公司 萘啶化合物及其用途
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
MA53726A (fr) 2018-09-25 2022-05-11 Incyte Corp Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr
TW202024053A (zh) * 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
EP3860980A1 (fr) * 2018-10-03 2021-08-11 F. Hoffmann-La Roche AG Composés de 8-aminoisoquinoline et leurs utilisations
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
MX2021005047A (es) 2018-10-31 2021-09-08 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
WO2020092528A1 (fr) * 2018-10-31 2020-05-07 Gilead Sciences, Inc. Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1
EP3894406A1 (fr) 2018-12-11 2021-10-20 Bayer Aktiengesellschaft Dérivés de pyrrolopyridine substitués
WO2020132384A1 (fr) 2018-12-21 2020-06-25 Celgene Corporation Inhibiteurs thiénopyridine de ripk2
AU2019413504A1 (en) * 2018-12-26 2021-06-03 Janssen Pharmaceutica Nv Thienopyridinone compounds
WO2020193511A1 (fr) 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv Inhibiteurs de hpk1
MA55478A (fr) 2019-03-26 2022-02-09 Janssen Pharmaceutica Nv Inhibiteurs bicycliques de hpk1
US20220242870A1 (en) * 2019-05-17 2022-08-04 Voronoi Inc. Heterocycle-fused pyrimidine derivative and use thereof
EP3972695A1 (fr) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1
CN114245807A (zh) 2019-06-25 2022-03-25 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
CA3147918A1 (fr) 2019-08-06 2021-02-11 Incyte Corporation Formes solides d'un inhibiteur d'hpk 1
MX2022002877A (es) 2019-09-13 2022-08-08 Nimbus Saturn Inc Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
CN112552293A (zh) * 2019-09-25 2021-03-26 珠海宇繁生物科技有限责任公司 一种protac小分子化合物及其应用
KR20220085796A (ko) 2019-10-18 2022-06-22 포티 세븐, 인코포레이티드 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
AU2020374947A1 (en) 2019-10-31 2022-03-31 Forty Seven, Inc. Anti-CD47 and anti-CD20 based treatment of blood cancer
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
AU2020412875A1 (en) 2019-12-24 2022-06-23 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
CN114981276A (zh) * 2020-01-09 2022-08-30 住友化学株式会社 杂环化合物和含有其的有害节肢动物防除组合物
MX2022009947A (es) 2020-02-14 2022-11-07 Jounce Therapeutics Inc Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
TW202203917A (zh) * 2020-04-13 2022-02-01 加拿大健康網路大學 治療細胞激素釋放症候群之方法
CN115698009A (zh) 2020-05-01 2023-02-03 吉利德科学公司 抑制cd73的2,4-二氧代嘧啶化合物
EP4149946A1 (fr) * 2020-05-11 2023-03-22 University Health Network Formes salines et cristallines de 4-amino-5-(6-(4-méthylpipérazin-1-yl)-1h-benzo[d]imidazol-2-yl)thiéno[2,3-b]pyridin-6(7h)-one
WO2021249913A1 (fr) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft Dérivés de 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azétidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate et des composés apparentés servant d'inhibiteurs de map4k1 (hpk1) pour le traitement du cancer
EP4222150A1 (fr) * 2020-09-30 2023-08-09 BeiGene, Ltd. Composés de 3-[(1h-pyrazol-4-yl)oxy]pyrazin-2-amine utilisés en tant qu'inhibiteur de hpk1 et leur utilisation
EP4240361A1 (fr) * 2020-11-09 2023-09-13 Merck Sharp & Dohme LLC Inhibiteurs, du type 2-aminoquinazoline à substitution 7-azole, de hpk1
US20240002394A1 (en) * 2020-11-24 2024-01-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Deuterium-modified thienopyridone compound
WO2022167627A1 (fr) 2021-02-05 2022-08-11 Bayer Aktiengesellschaft Inhibiteurs de map4k1
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
CN116888127A (zh) * 2021-03-10 2023-10-13 轩竹生物科技股份有限公司 三并环类hpk1抑制剂及其用途
CN116981666A (zh) * 2021-03-26 2023-10-31 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
WO2022226667A1 (fr) * 2021-04-30 2022-11-03 Ontario Institute For Cancer Research (Oicr) Composés aminopyridine substitués utilisés en tant qu'inhibiteurs de la kinase progénitrice hématopoïétique 1 (hpk1)
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
WO2022253252A1 (fr) * 2021-06-03 2022-12-08 Silexon Biotech Co., Ltd. Composés hétérocycliques utiles en tant qu'inhibiteurs de hpk1
CN115433161A (zh) * 2021-06-04 2022-12-06 轶诺(浙江)药业有限公司 新型hpk1抑制剂及其制备方法和应用
IL309378A (en) 2021-06-23 2024-02-01 Gilead Sciences Inc DIACYLGLYERCOL KINASE MODULATING COMPOUNDS
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
WO2022271684A1 (fr) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Composés modulant les diacylglycérol kinases
EP4359411A1 (fr) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Composés modulant les diacylglycérol kinases
WO2023001794A1 (fr) 2021-07-20 2023-01-26 Astrazeneca Ab Pyrazine-2-carboxamides substituées utilisées en tant qu'inhibiteurs de hpk1 pour le traitement du cancer
WO2023015199A1 (fr) * 2021-08-03 2023-02-09 Nimbus Saturn, Inc. Antagonistes de hpk1 et leurs utilisations
WO2023023942A1 (fr) * 2021-08-24 2023-03-02 Biofront Ltd (Cayman) Inhibiteurs de hpk1, compositions comprenant un inhibiteur de hpk1 et leurs procédés d'utilisation
WO2023057882A1 (fr) * 2021-10-05 2023-04-13 Pfizer Inc. Combinaisons de composés d'azalactam avec un antagoniste de liaison à l'axe pd-1 pour le traitement du cancer
CA3233233A1 (fr) * 2021-10-15 2023-04-20 Ruben Abagyan 1h-pyrazolo[4,3-c]quinoleines substituees, leurs procedes de preparation et leur utilisation
WO2023076983A1 (fr) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Dérivés de pyridine-3(2h)-one
WO2023077030A1 (fr) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Composés cd73
WO2023107956A1 (fr) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Protéines se liant à nkg2d, cd16 et 5t4
WO2023107954A1 (fr) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Anticorps ciblant 5t4 et leurs utilisations
TW202333754A (zh) * 2021-12-17 2023-09-01 大陸商海思科醫藥集團股份有限公司 並環雜環衍生物及其在醫藥上的應用
WO2023122615A1 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations
TW202333712A (zh) * 2021-12-22 2023-09-01 加拿大健康網路大學 於急性骨髓性白血病或淋巴瘤之治療
WO2023122581A2 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de dégradation de doigt de zinc de la famille ikaros et utilisations associées
WO2023138612A1 (fr) * 2022-01-19 2023-07-27 Silexon Ai Technology Co., Ltd. Composés hétérocycliques utiles en tant qu'inhibiteurs de hpk1
WO2023143384A1 (fr) * 2022-01-27 2023-08-03 四川海思科制药有限公司 Composé pour inhiber ou dégrader la kinase hpk1 et son utilisation médicale
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023151559A1 (fr) * 2022-02-08 2023-08-17 和径医药科技（上海）有限公司 Composé hétérocyclique, composition pharmaceutique le contenant et utilisation anti-tumorale associée
EP4245756A1 (fr) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Agents de dégradation de la famille des doigts de zinc de l'ikaros et leurs utilisations
WO2023183817A1 (fr) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Polythérapie pour le traitement de cancers exprimant trop -2
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
WO2023205719A1 (fr) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Composés modulateurs de kras g12d
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021615A1 (fr) * 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
ES2235970T3 (es) * 1999-10-19 2005-07-16 MERCK & CO. INC. Inhibidores de tirosina quinasa.
US6756383B2 (en) 2000-09-01 2004-06-29 Chiron Corporation Heterocyclic derivatives of quinolinone benimidazoles
WO2004014375A2 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Inhibiteurs de metalloprotease bicycliques condenses
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
US8501750B2 (en) 2007-05-21 2013-08-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
ES2584278T3 (es) 2008-04-11 2016-09-26 Merck Patent Gmbh Derivados de tienopiridona como activadores de la proteína quinasa activada por AMP (AMPK)
PT2280952E (pt) 2008-05-05 2012-09-28 Merck Patent Gmbh Derivados de tienopiridona como ativadores da proteína-cinase ativada por amp (ampk)
CN103476767B (zh) 2011-02-09 2015-06-10 弗·哈夫曼-拉罗切有限公司 作为pi3激酶抑制剂的杂环化合物
GB201114212D0 (en) * 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
LT3322711T (lt) * 2015-06-25 2021-05-10 University Health Network Hpk1 inhibitoriai ir jų panaudojimo būdai

Also Published As

Publication number Publication date
PL3322711T3 (pl) 2021-10-25
HRP20210895T1 (hr) 2021-08-20
EA201890059A1 (ru) 2018-07-31
BR122023006150B1 (pt) 2023-12-12
JP6898868B2 (ja) 2021-07-07
TWI733679B (zh) 2021-07-21
MA42456A (fr) 2018-05-23
IL283353A (en) 2021-07-29
CN107922431B (zh) 2021-06-04
US20220002313A1 (en) 2022-01-06
WO2016205942A1 (fr) 2016-12-29
IL256250A (en) 2018-02-28
JP2018522858A (ja) 2018-08-16
JP2021138754A (ja) 2021-09-16
CN107922431A (zh) 2018-04-17
PT3322711T (pt) 2021-05-13
US20180179221A1 (en) 2018-06-28
CN113214287A (zh) 2021-08-06
BR112017027241B1 (pt) 2023-09-26
RS61919B1 (sr) 2021-06-30
MX2021011435A (es) 2021-10-13
MX2018000048A (es) 2018-06-06
TW201718597A (zh) 2017-06-01
ES2872555T3 (es) 2021-11-02
SI3322711T1 (sl) 2021-08-31
LT3322711T (lt) 2021-05-10
KR102614872B1 (ko) 2023-12-15
CA2989684A1 (fr) 2016-12-29
EP3322711A1 (fr) 2018-05-23
BR112017027241A2 (fr) 2018-08-21
AU2016282289A1 (en) 2018-01-04
DK3322711T3 (en) 2021-04-26
CY1124489T1 (el) 2022-07-22
MD3322711T2 (ro) 2021-07-31
MA42456B1 (fr) 2021-06-30
US10501474B2 (en) 2019-12-10
JP2023071911A (ja) 2023-05-23
CN113214287B (zh) 2023-10-20
AU2016282289B2 (en) 2020-12-24
HUE054159T2 (hu) 2021-08-30
EA035421B1 (ru) 2020-06-11
KR20180015255A (ko) 2018-02-12
IL256250B (en) 2021-06-30
KR20240000617A (ko) 2024-01-02
HK1255833A1 (zh) 2019-08-30
EP3322711A4 (fr) 2018-12-19
EP3322711B1 (fr) 2021-03-10
IL283353B (en) 2022-09-01
US11059832B2 (en) 2021-07-13
US20200190104A1 (en) 2020-06-18
JP7241810B2 (ja) 2023-03-17

Similar Documents

Publication Publication Date Title
IL283353A (en) hpk1 inhibitors and methods of using them
HK1249513A1 (zh) Kras的稠合三環抑制劑及其使用方法
HK1259232A1 (zh) Menin-mll的取代抑制劑及其使用方法
HK1252693A1 (zh) Egfr抑制劑及其使用方法
HK1246286A1 (zh) Lrrk2抑制劑及其製備和使用方法
HK1250236A1 (zh) 用gdf8抑制劑增加力量和功能的方法
EP3268369A4 (fr) Inhibiteurs anti-intégrine alphavbeta1 et méthodes d'utilisation associées
IL267291A (en) Actonucleotidase inhibitors and methods of using them
HK1253049A1 (zh) 糖基相互作用化合物及其使用方法
GB201514756D0 (en) Compound and method of use
IL259801A (en) ezh2 inhibitors and methods of using them
HK1249497A1 (zh) Ebna1抑制劑及其使用方法
GB201514760D0 (en) Compounds and method of use
IL282482A (en) Variants of protoxin-II and methods of use
IL282508A (en) Variants of protoxin-II and methods of use
HK1257171A1 (zh) 間變性淋巴瘤激酶（alk）和絲氨酸富集蛋白激酶 （sppk）的抑制劑及其使用方法
HK1248684A1 (zh) Usp7抑制劑化合物及使用方法
GB2544343B (en) Receptacle and its method of manufacture
IL266344A (en) Inhibitors of mtor-deptor interactions and methods of use thereof
PT3268376T (pt) Inibidores de enolase e métodos de tratamento com os mesmos
GB201416797D0 (en) Contianer and method of use thereof